Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Steffel

Showing results (131-140 of 204) with videos related to

Pageof 21
Sort By:
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|November 22, 2018
Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trialJan Steffel, Christian T Ruff, Eugene Braunwald, et al.
European Journal of Heart Failure|October 31, 2023
Long-term outcome after upgrade to cardiac resynchronization therapy: A propensity score-matched analysisSander Trenson, Gabor Voros, Pieter Martens, et al.
International Journal of Cardiology|March 28, 2015
Increased prothrombotic profile in the left atrial appendage of atrial fibrillation patientsAlexander Breitenstein, Martina Glanzmann, Volkmar Falk, et al.
The American Journal of Medicine|May 29, 2018
Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery DiseaseRenato D Lopes, Jan Steffel, Manuela Di Fusco, et al.
ESC Heart Failure|July 30, 2025
Patient-specific modifiers of survival benefit in cardiac resynchronization therapy - A multicentre interaction analysisBert Vandenberk, Marius Brusselmans, Gabor Voros, et al.
Journal of Clinical Medicine|April 13, 2024
Landmark Evolutions in Time and Indication for Cardiac Resynchronization Therapy: Results from a Multicenter Retrospective RegistryJeroen Bijnens, Sander Trenson, Gabor Voros, et al.
The American Journal of Medicine|August 11, 2020
Corrigendum to "Effectiveness and Safety of Oral Anticoagulants in Adults with Non-valvular Atrial Fibrillation Patients and Concomitant Coronary/Peripheral Artery Disease" American Journal of Medicine 131:09 (2018): 1074-1085.e4Renato D Lopes, Jan Steffel, Manuela Di Fusco, et al.
JAMA Cardiology|July 10, 2024
Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical TrialAndré Zimerman, Eugene Braunwald, Jan Steffel, et al.
ESC Heart Failure|July 12, 2020
Differential effect of cardiac resynchronization therapy in patients with diabetes mellitus: a long-term retrospective cohort studyPeter C Kahr, Sander Trenson, Matthias Schindler, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 6, 2010
Histamine H1 receptor promotes atherosclerotic lesion formation by increasing vascular permeability for low-density lipoproteinsIzabela Rozenberg, Susanna H M Sluka, Lucia Rohrer, et al.
Pageof 21

Showing results (131-140 of 204) with videos related to

Sort By:
Pageof 21
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|November 22, 2018
Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trialJan Steffel, Christian T Ruff, Eugene Braunwald, et al.
European Journal of Heart Failure|October 31, 2023
Long-term outcome after upgrade to cardiac resynchronization therapy: A propensity score-matched analysisSander Trenson, Gabor Voros, Pieter Martens, et al.
International Journal of Cardiology|March 28, 2015
Increased prothrombotic profile in the left atrial appendage of atrial fibrillation patientsAlexander Breitenstein, Martina Glanzmann, Volkmar Falk, et al.
The American Journal of Medicine|May 29, 2018
Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery DiseaseRenato D Lopes, Jan Steffel, Manuela Di Fusco, et al.
ESC Heart Failure|July 30, 2025
Patient-specific modifiers of survival benefit in cardiac resynchronization therapy - A multicentre interaction analysisBert Vandenberk, Marius Brusselmans, Gabor Voros, et al.
Journal of Clinical Medicine|April 13, 2024
Landmark Evolutions in Time and Indication for Cardiac Resynchronization Therapy: Results from a Multicenter Retrospective RegistryJeroen Bijnens, Sander Trenson, Gabor Voros, et al.
The American Journal of Medicine|August 11, 2020
Corrigendum to "Effectiveness and Safety of Oral Anticoagulants in Adults with Non-valvular Atrial Fibrillation Patients and Concomitant Coronary/Peripheral Artery Disease" American Journal of Medicine 131:09 (2018): 1074-1085.e4Renato D Lopes, Jan Steffel, Manuela Di Fusco, et al.
JAMA Cardiology|July 10, 2024
Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical TrialAndré Zimerman, Eugene Braunwald, Jan Steffel, et al.
ESC Heart Failure|July 12, 2020
Differential effect of cardiac resynchronization therapy in patients with diabetes mellitus: a long-term retrospective cohort studyPeter C Kahr, Sander Trenson, Matthias Schindler, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 6, 2010
Histamine H1 receptor promotes atherosclerotic lesion formation by increasing vascular permeability for low-density lipoproteinsIzabela Rozenberg, Susanna H M Sluka, Lucia Rohrer, et al.
Pageof 21